

(12) **UK Patent Application** (19) **GB** (11) **2 398 497** (13) **A**

(43) Date of A Publication 25.08.2004

(21) Application No: 0303843.7

(22) Date of Filing: 19.02.2003

(71) Applicant(s):
Omega Bio-Pharma (I.P.2) Limited
Unit 714, 7/F, Miramar Tower,
1-23 Kimberley Road, Tsimshatsui,
Hong Kong

(72) Inventor(s):
Francis Chi
Qin Tang Wen
Zanming Shen

(74) Agent and/or Address for Service:
Lloyd Wise
Commonwealth House,
1-19 New Oxford Street, LONDON,
WC1A 1LW, United Kingdom

(51) INT CL⁷:
A61K 31/145 // A61P 37/04

(52) UK CL (Edition W):
A5B BHA B180 B40Y B404 B41Y B411
U1S S2411

(56) Documents Cited:
WO 2003/009699 A2 **WO 2002/048110 A2**
WO 2000/066110 A1 **WO 1999/039707 A1**
FR 002716625 A1 **US 5605885 A**
US 4657932 A
H.Bryant et al, J of Pharmacology and Experimental
Therapeutics, 1989, 249(2), 424-429

(58) Field of Search:
INT CL⁷ A61K 31/13 31/131 31/145, A61P 37/04
Other: ONLINE: CAS-ONLINE, EPODOC, JAPIO, TXTE
& WPI

(54) Abstract Title: **Composition for improving immunity of animals**

(57) There is provided a new use of cysteamine, a salt thereof, or a composition containing cysteamine or a salt thereof, for improving immunity of animals.

GB 2 398 497 A

Original Printed on Recycled Paper

COMPOSITION FOR IMPROVING IMMUNITY OF ANIMALS

The present invention relates to the use of cysteamine or a cysteamine-containing composition for modulating immunity
5 of animals, and in particular, improving immunity of vertebrate animals.

The survival of animals relies on an effective immune system. The immune system of animals and in particular
10 vertebrate animals, made up of many organs and cells, defends the body against infection, disease and foreign substances such as viruses and bacteria. There have been proposed various compositions for boosting the immunity of the body for treating diseases or simply to improve the
15 general well being of the body. For example, some pharmaceuticals for HIV infection treat the HIV-infected patients by seeking to improve the general immunity of the patients. However, these pharmaceuticals are not always reliable and they tend to cause many undesirable side
20 effects.

It is thus an object of the present invention in which the above issues are addressed, or at least to provide a useful alternative to the public. The present invention provides

a composition for use in modulating the immunity of animals; the composition may be used by itself or in combination with other existing compositions or pharmaceuticals.

5

According to a first aspect of the present invention, there is provided the use of cysteamine, a salt thereof, or a composition containing cysteamine or a salt thereof, for improving immunity of animals.

10

According to a second aspect of the present invention, there is provided a composition for improving immunity of animals, comprising cysteamine, a salt thereof, or a composition containing cysteamine or a salt thereof.

15

According to a third aspect of the present invention, there is provided an animal feed additive for improving immunity of animals comprising a composition as described above.

20 According to a fourth aspect of the present invention, there is provided an animal feed for improving immunity of animals comprising a composition as described above.

According to a fifth aspect of the present invention, there is provided a method of improving immunity of animals, comprising administering cysteamine, or a salt thereof, or
5 a composition containing cysteamine or a salt thereof, into the animals.

Improving immunity may include increasing the level of interleukin-2 (IL-2) in the animals. Improving immunity
10 may also include increasing the level of interleukin-6 (IL-6) in the animals. In particular, improving immunity may also include stimulating production of lymphocytes in the animals. Studies have shown that a higher level of IL-2 or IL-6 corresponds to a generally stronger immune system. It
15 has been identified that the above use is particularly effective in vertebrate animals such as cattle and poultry.

Preferably, the composition may comprise 1 to 95wt% of cysteamine, or a salt thereof, and an inclusion compound
20 host materials composition comprising a stabilizer selected from a group including cyclodextrin and its derivatives. Suitably, the cysteamine-containing composition may comprise 1 to 75wt% of cysteamine or a salt thereof. More

suitably, the cysteamine-containing composition may comprise 1 to 40wt% cysteamine or a salt thereof.

Preferably, the cysteamine-containing composition may
5 comprise 1 to 60wt% of the inclusion compound host materials composition. Suitably, the cysteamine-containing composition may comprise 10 to 40wt% of the inclusion compound host materials composition. The stabilizer
10 composition may be selected from a group including cyclodextrin (-CD), methyl β -cyclodextrin (M- β -CD), hydropropyl β -cyclodextrin (HP- β -CD), hydroethyl β -cyclodextrin (HE- β -CD), poly-cyclodextrin, ethyl β -cyclodextrin (E- β -CD) and branched cyclodextrin.

15

Preferably, the cysteamine-containing composition may comprise at least one of fillers, disintegrants, binders, flavorings and smelling agents, and coating materials. In particular, the cysteamine-containing composition may
20 comprise 1 to 20wt% of the coating materials. Advantageously, the coating materials may be enteric, and selected from a group including cellulose acetate phthalate, starch acetate phthalate, methyl cellulose

phthalate, glucose or fructose derivatives from phthalic acid, acrylic and methacrylic copolymers, polymethyl vinyl ether, partly esterified substance of maleic anhydride copolymer and formogelatine.

5

Preferably, the cysteamine-containing composition may comprise 1 to 90wt% of the fillers. Suitably, the cysteamine-containing composition may comprise 1 to 60wt% of the fillers, and the fillers may be selected from a group including powdered cellulose, starch and calcium sulfate.

Preferably, the cysteamine-containing composition may comprise 5 to 50wt% of the binders and the disintegrants. Suitably, the cysteamine-containing composition may comprise 15 to 35wt% of the binders and the disintegrants. The binders and the disintegrants may be selected from a group including hydropropyl starch, microbial alginate, microcrystalline cellulose and starch.

20

Preferably, the cysteamine-containing composition may comprise 0.05 to 0.3wt% of the flavoring and smelling agents for enhancing the flavor thereof.

Suitably, the cysteamine-containing composition may be formed into granules, each of which comprises at least one layer of the coating materials. The cysteamine-containing composition may preferably be formed into granules in which
5 the cysteamine or a salt thereof is shielded from its surroundings by the inclusion compound host materials composition. Each of the granules of the cysteamine-containing composition may have a size ranging from 0.28 to 0.90mm in diameter. The granules with this range of size
10 can be more easily swallowed by the animals. The cysteamine-containing composition may preferably be encapsulated by the enteric coating materials.

The cysteamine-containing composition may be used for the
15 manufacture of an animal feed additive. The cysteamine-containing composition may also be used for the manufacture of an animal feed. In particular, the cysteamine-containing composition may be adapted for oral administration into animals. However, cysteamine for
20 improving immunity in animals may be administered to animals by other means such as by direct injection.

The present invention is based on the demonstration that cysteamine or a cysteamine-containing composition when

administered to animals such as cows has activity in modulating immunity and in particular improving immunity thereof. Prior to this finding, there was no suggestion or sufficient indication that cysteamine or its variants or derivatives might have such activity. The present invention also provides a feed and a feed additive for improving immunity of animals and a method for improving immunity of animals.

One effect of cysteamine is described in PRC Patent Publication No. CN 1358499 and International Patent Publication No. WO02/48110, the content of which is incorporated herein. However, a previously unknown effect of cysteamine is its effect on improving immunity of animals. The effect of cysteamine or a cysteamine-containing composition on the immunity of animals is explained as follows. It is believed that cysteamine having a physiological activity acts as a growth stimulator. Natural cysteamine is a part of coenzyme A (also know as CoA-SH or CoA) which is a coenzyme pattern of pantothenic acid. In the course of metabolism, coenzyme A acts as the carrier of dihydrosulfuryl or variants of hydrosulfuryl which is linked with the hydrosulfuryl of coenzyme A.

Experiments performed on other animals such as pigs, poultry, fowls, goats, rabbits and fish have shown that cysteamine can deplete somatostatin (SS) in the animals.

5 This increases the level of growth hormone in the blood of the animals which at the same time raises the level of various other growth stimulating factors including insulin-like growth factor I (IGF-I), insulin, triiodothyronine (T3), thyroxine (T4) and beta-endorphin (beta-END).

10

As regards the present invention, it is shown that cysteamine can improve immunity by increasing the level of interleukin-2 (IL-2) and/or interleukin-6 (IL-6).

15 IL-2 belongs to a class of soluble, regulatory proteins known as cytokines. IL-2 is a 133-amino acid glycoprotein secreted by T(H) lymphocytes and other cells following activation by antigens, mitogens and other cytokines. IL-2 stimulates the proliferation and cytotoxicity of T
20 lymphocytes, enhances the microbicidal and cytotoxic activities of NK cells, B-lymphocytes, macrophages and monocytes (Sule NS, Nerurkar RP, Kamath S; 2001; Interleukin-2 as a therapeutic agent; J Assoc Physicians

India. 49:897-900). It is shown that IL-2 represents an important role in the immune system.

Studies have shown that IL-2 leads to the curtailment of HIV spreading in HIV infected patients of all stages of HIV disease (Paredes R, Lopez Benaldo de Quiros JC, Fernandez-Cruz E, Clotet B, Lane HC; 2002; The potential role of interleukin-2 in patients with HIV infection. AIDS Rev 4(1):36-40). IL-2 is also a promising immunotherapeutic agent mediating the regression of established growing cancers (Rosenberg SA.200; Progress in the development of immunotherapy for the treatment of patients with cancer; J Intern Med 250(6):462-75), metastatic melanoma, acute myelogenous leukemia and metastatic renal cell carcinoma (Atkins MB;2002; Interleukin-2: clinical applications; Semin Oncol 29(3 Suppl 7):12-7)in humans.

However, at the time of filing this application, it has been about fifteen years since the first positive clinical reports of IL-2 appeared in the medical literature, ten years since moderate dose continuous infusion IL-2 was approved in Europe and five years since high-dose bolus IL-2 was approved for general use in the United States when IL-2 has been accepted as a standard treatment to be used

alone or in combination with chemotherapy or biotherapy in the management of diseases (Dillman RO.1999. What to do with IL-2? Cancer Biother Radiopharm 14(6):423-34). It took a relatively long time before IL-2 has been widely accepted
5 to be used for improving the immunity in animals.

Numerous reports have shown the immunomodulatory capabilities of recombinant (rb) IL-2 on important mammary immune cell functions. *In vitro* and *in vivo*
10 studies indicate that rbIL-2 markedly enhances the proliferation of mononuclear cells (Torre, PM. Konur PK. and Oliver SP; 1992; Proliferative response of mammary gland mononuclear cells to recombinant bovine interleukin-2; Vet; Immunol. Immunopathol. 32:351).
15 Studies have shown that lymphocyte populations isolated from mammary tissues increase cytotoxic and bactericidal activities following *in vitro* culture with IL-2 (Shafer-Weaver KA. and Sordillo LM; 1996; Enhancing bactericidal activity of bovine lymphoid cells during the peripartum period; J.Dairy Sci. 79:1347) (Sordillo LM. Campos M. and Babiuk LA; 1991; Antibacterial activity of bovine mammary gland lymphocytes following treatment with interleukine-2; J. Dairy Sci. 74:3370).

Turning to IL-6, IL-6 has effects on most of the major effector cells of the immune system, including B-lymphocytes, helper T-lymphocytes, cytotoxic T-lymphocytes, and killer cells. In B-lymphocytes cultured *in vitro*, IL-6
5 is essential as a late-stage differentiation factor during the transition of B-cells into immunoglobulin-secreting plasma cells. Furthermore, IL-6 has been shown to augment secondary, but not primary, antibody responses *in vivo*. These and other data suggested that IL-6 plays a major role
10 in the development of antigen-specific immune responses.

Many studies have shown that IL-6 can affect the proliferation of both peripheral and thymic T-cells. Furthermore, IL-6 can stimulate the differentiation of
15 cytotoxic T-cells from the thymic precursors. IL-6 has been shown to augment the activity of natural killer cells.

Recent studies on cytokine function in hematopoiesis have shown that IL-6 cooperates with interleukin-3 (IL-3) in
20 enhancing stem-cell differentiation.

The role of IL-6 *in vivo* in inflammation is to initiate the hepatic responses of production of acute-phase protein, such as collagenase, stromelysin, and the 72-kDa

gelatinase, which enzymatically degrade connective tissue matrix. IL-6 probably also plays a role in inflammation at local tissue sites by modulating the balance of tissue-degrading activity. (Richards CD, Scamurra RW, and
5 Murtaugh MP. Interleukin-6. p155-157. In: Cytokines in animal health and disease. 1995. Edited by Michael J. Myers and Michael P. Murtaugh. Marcel Dekker, Inc. New York, Basel, Hong Kong)

10 Two kinds of effector mechanisms mediate immune responses. Specific molecules, called antibodies, mediate some immune responses. The synthesis of antibodies occurs in a subset of lymphocytes called B-lymphocytes or B-cells. Antibody-mediated immunity is called humoral immunity. Other immune
15 responses are mediated by cells. All types of leukocytes in the blood participate in cell-mediated immunity. However, the specificity of the response depends upon a subset of lymphocytes called T-lymphocytes or T-cells. The mature T-cells include Helper T-cell, cytotoxic suppressor
20 T-cell, and memory T-cell. Helper T-cells are required to initiate immune responses by recognizing foreign antigens and releasing factors that will promote the responses of other lymphocytes (B-cells and T-cells) to that antigen. Cytotoxic T-cells, on coming into contact with a target

cell, deliver a "lethal hit" to destroy target cells, such as tumor or foreign cells.

Certain natural compounds have the ability to cause lymphocytes to divide. The most important of these compounds is a family of proteins called lectins, which are usually isolated from plants. Examples of lectins include phytohemagglutnin (PHA) which is obtainable from red kidney bean (*Phaseolus vulgaris*), and concanavalin A (Con A) which is obtainable from jack bean (*canavalis ensiformis*). These lectins have the ability to specifically bind sugars on lymphocyte membrane to stimulate nucleoside incorporation, phospholipid synthesis, DNA synthesis, and cell division. PHA stimulates primarily T-cell division. These mitogens can be used to assist in the differentiation of T-cells and, by measurement of the response provoked, demonstrate the ability of the T-cell system to respond to nonimmunologic stimuli (Sule NS, Nerurkar RP, Kamath S. 2001. Interleukin-2 as a therapeutic agent. J Assoc Physicians India. 49:897-900).

The present invention teaches the use of cysteamine for improving immunity of animals. It is believed that cysteamine depletes the level of somatostatin and increases


the level of growth hormone, and this results in an increase of mitogen-induced lymphocyte proliferation. In particular, the present invention uses a cysteamine-containing composition, a compound of cysteamine enveloped in microcapsule. The following experiments seek to demonstrate the effect of cysteamine or the cysteamine-containing composition on the immune system and immunity of animals. The experiments also seek to demonstrate the effect of cysteamine or the cysteamine-containing composition on the concentration of serum IL-2 and the concentration of plasma IL-6 in the animals.

The cysteamine-containing composition suitable for use in the present invention comprises two main ingredients of 1 to 95wt% of cysteamine (or its salts, for example, cysteamine hydrochloride, or other pharmaceutically acceptable acid addition salts thereof) and 1 to 80wt% of a carrier such as inclusion compound host materials. The chemical formula of cysteamine is $\text{HSCH}_2\text{CH}_2\text{NH}_2$. The term "cysteamine" referred hereinafter means cysteamine and/or its salt like compounds. Cysteamine and its salts are well known in the chemical literature.

The general chemical formula of a cysteamine salt is $C_2H_7NS.X$, where X may be HCl, H_3PO_4 , bitartrate, salicylate, etc. The cysteamine used is preferably of pharmaceutically acceptable standard and the content of carbon, hydrogen, nitrogen and sulfur therein are substantially 31.14wt%, 9.15wt%, 18.16wt% and 41.56wt% respectively. While the workable content of cysteamine in the cysteamine-containing composition ranges from 1 to 95wt%, a preferable range of 1 to 75wt% and a more preferable range of 1 to 40wt% of cysteamine may be used. Cysteamine is one of the main active ingredients of the cysteamine-containing composition. However, it has been identified that if the content of cysteamine in the cysteamine-containing composition exceeds 95wt%, mixing the composition with a basal feed would be rather difficult and the effect of the composition for improving immunity of the animals would be hindered.

The inclusion compound host materials may comprise mainly cyclodextrin and/or its derivatives which are selected from a group including methyl β -cyclodextrin (M- β -CD), hydropropyl β -cyclodextrin (HP- β -CD), hydroethyl β -cyclodextrin (HE- β -CD), polycyclodextrin, ethyl β -

cyclodextrin (E- β -CD) and branched cyclodextrin. The general chemical formula of cyclodextrin is $(C_6O_5H_9)_n \cdot (C_6O_5H_9)_2$ and the structural formula is as follows.



where α -CD $n=4$; β -CD $n=5$; γ -CD $n=6$. (Cyclodextrin is a cyclic oligomer of alpha-D-glucopyranose.)

10 It is worthwhile to note that the β -CD form of cyclodextrin is preferably used because the internal diameter of its molecule is about 6-8Å which makes it a particular suitable candidate as an inclusion compound host material for

15 preparation of the cysteamine-containing composition, which involves the use of an inclusion process. The term "cyclodextrin" referred hereinafter means cyclodextrin and/or its derivatives. Any derivative of cyclodextrin which has the property of stabilizing and protecting

20 cysteamine from degradation may be used. For example, any one of the groups of cyclodextrin or its derivatives mentioned above may be used.

While the workable content of the inclusion compound host materials in the cysteamine-containing composition ranges from 1 to 80wt%, a preferable workable range of 1 to 60wt% and a more preferable workable range of 10 to 40wt% of the inclusion compound host materials may also be used. The actual amount of the inclusion compound host materials used will depend on the actual content of the cysteamine used in preparing the cysteamine-containing composition.

10 The cysteamine-containing composition may also comprise 1 to 90wt% of fillers although a preferable workable range of 1 to 60wt% and a more preferable workable range of 1 to 40wt% of the fillers may also be used in the composition. The actual content will depend on the actual amount of
15 cysteamine and inclusion compound host materials used. The fillers may be selected from a group including powdered cellulose, starch and calcium sulfate (e.g. $\text{CaSO}_4 \cdot 2\text{H}_2\text{O}$). It is to be noted that if the content of the fillers exceeds 90wt% in the cysteamine-containing composition, the content
20 of the main active ingredients will thus be reduced, and the cysteamine-containing composition may become less effective in improving immunity of the animals administered therewith.

The cysteamine-containing composition may also comprise 5 to 50wt% of disintegrants and binders although a preferable workable range of 10 to 40wt% and a more preferable workable range of 15 to 35wt% may also be used. The actual content will depend on the actual amount of cysteamine, the inclusion compound host material and other ingredients used. The binders and disintegrants may be selected from a group including hydropropyl starch, microbial alginate, microcrystalline cellulose and starch. It has been identified that if the content of the disintegrants and binders in the composition is less than 5wt%, granules of the composition produced will lack the required hardness.

In addition, manufacturing of the composition would become very difficult. If however the content of the disintegrants and binders is more than 50wt%, the resulting composition will have excessive hardness, this is especially so if the content of binders represents a large portion of the mixture of the disintegrants and binders. This will result in difficult absorption of the composition by the intestines of the animals.

The cysteamine-containing composition may also comprise 0.05 to 0.3wt% of flavoring and smelling agents which may be a flavoring essence.

5 The cysteamine-containing composition may also comprise 1 to 20wt% of coating materials although a preferable workable range is 1 to 15wt% and a more preferable workable range is 2 to 10wt%. The actual content will depend on the actual amount of cysteamine, the inclusion compound host
10 materials and the other ingredients used. The coating materials are preferably enteric-coated which allows dissolution in an alkaline environment such as in the intestines. The coating materials may be made of and selected from a group including cellulose acetate
15 phthalate, starch acetate phthalate, methyl cellulose phthalate, glucose or fructose derivatives from phthalic acid, acrylic and methacrylic copolymers, polymethyl vinyl ether, partly esterified substance of maleic anhydride copolymers, lac and formogelatine. It has been identified
20 that if the content of the coating materials is less than 1wt%, granules of the composition may not be entirely covered by the coating materials which act as a protective layer. The cysteamine-containing composition may thus degrade before being absorbed by the intestines into the

bloodstream of the animals. On the other hand, if the content of the coating materials exceeds 15wt%, the active ingredients in the composition may not effectively be released from the composition. Thus, the intended
5 modulation of immunity would not be achieved.

The cysteamine-containing composition used in the present invention is in the form of small granules each of which has a preferable diameter of substantially 0.28 to 0.90mm.
10 These granules are prepared using a micro-encapsulation method. The method involves using a macromolecular substance having inclusion property. The macromolecular substance may be the inclusion compound host materials (which may comprise mainly cyclodextrin) as described
15 above. The macromolecular substance acts as a molecular capsule to engulf the molecules of cysteamine, whereby cysteamine in the composition is protected and insulated from light, heat, air and moisture of the surroundings. The stability of cysteamine is thus preserved. The
20 inclusion compound host materials used in the micro-encapsulation method preferably comprises a cyclic polysaccharide compound having 6 to 12 glucose molecules, which is produced by reacting cyclodextrin glycosidtransferase and starch in the presence of *Bacillus*.

Various studies using acute, sub-acute and chronic toxic tests have shown that the macromolecular substance is non-toxic. Subsequent to the micro-encapsulation process, each granule may be coated with at least one and preferably a plurality of layers of the coating materials described above. The following provides a more detailed description of a method of preparing the cysteamine-containing composition used in the present invention.

10 In a jacketed reactor linked with polytetrafluoroethylene and equipped with a polytetrafluoroethylene coated stirrer, 4080g of 75wt% cysteamine hydrochloride solution in ethanol is added with mainly nitrogen being the atmosphere. The purity, melting point and burning residue of the cysteamine
15 used are preferably 98% or above, 66 to 70°C and 0.05% or below respectively. 1200g β -cyclodextrin is then added into the reactor similarly under the protection of nitrogen gas. (The quality of β -cyclodextrin is in accordance with the requirements for a food additive. In particular, the dry
20 basis purity is more than 98%; the weight loss by drying is less than 10.0%; the burning residue is less than 0.2%; the content of heavy metal is less than 10ppm; the arsenic content is less than 2ppm.) The mixture is then heated for 3 hours at 40°C. Heating is then stopped and stirring

continues for two hours thereafter, products resulted therefrom are then grounded and sieved through a screen (e.g. 40-mesh) filter after the products have been vacuum dried at a temperature of 40-50°C. All parts of the equipment, which may come in contact with the ingredients of the composition, should preferably be made of stainless steel.

In a tank-type mixer, 4200g (on dry basis) of the cysteamine which has undergone the inclusion process as described, 2600g of the fillers, and 1200g of the disintegrants and 1700g binders are added under the protection of a dry surroundings. These ingredients are then thoroughly mixed, and a suitable amount of anhydrous ethanol may be added and then mixed therewith. The resulting mixture presents a soft material with moderate hardness, so that it can be shaped into a ball by a light hold of palms. The ball-shaped resulting mixture may then be broken up by a light touch. After the mixture is pelleted by a granulator under the protection of nitrogen, the small granules resulting therefrom are immediately introduced to a fluid-bed dryer, and are then dried at the temperature of 40-50°C in a substantially vacuum environment.

Enteric coating materials are then prepared by a method with the following formulation: cellulose acetate phthalate 8.0g, polyethylene glycol terephthalate 2.4 ml, ethyl acetate 33.0ml and isopropyl acetate 33.6 ml. The resultant granules obtained above are uniformly coated under the protection of nitrogen with at least one layer but preferably a plurality of layers of the enteric coating materials described above. The enteric coating materials are dissolvable only at an alkaline environment. This can prevent the cysteamine from prematurely escaping from the composition or otherwise being degraded while it is still in the stomach of the animal. Cysteamine can adversely stimulate gastric mucous of the stomach of the animals. It is however worthwhile mentioning that cysteamine has relatively little side effects otherwise.

The resultant granules of the cysteamine-containing composition are then dried completely in a vacuum dryer at a temperature of 40 to 50°C. Then, all solvents are removed. The resultant granules are then allowed to cool to room temperature, and the micro-capsula were mixed with a suitable amount of flavoring and smelling agents by a cantilever double helix blender. The cysteamine-containing

composition is a microcapsule with its interior having cysteamine hydrochloride and cyclodextrin, and with its exterior coated with the enteric coating materials.

5 The composition produced will exhibit small granular (or micro-particulate) shape having smooth surface, good flow property, and is easy to blend with various animal feeds. The diameter of each granule of the composition is preferably 0.28 to 0.90mm. The composition also has
10 excellent stability. It has been found that after the composition is packaged with sealed plastic bags and stored for one year in a cool, dark and dry place, their properties remain unchanged. Therefore, they meet the requirements for a feed additive.

15

The composition having the particular construction described above has a number of functional advantages over cysteamine by itself. Firstly, the activity of the cysteamine contained in the composition is preserved after
20 it has been produced. This is important as the composition may be used as a feed additive and stored for a relatively long period of time before use. Secondly, the composition does not cause any noticeable gastro side effects to the animals fed therewith. Thirdly, the activity of the

composition is preserved not only during storage but more importantly until it reaches the intestines of the animals. Fourthly, the composition can be easily administered to farm animals on a large-scale basis cost-effectively because it can be readily mixed with any basal feed. No separate procedure or injection is needed at all.

Various experiments have been conducted to demonstrate that administering a feed having cysteamine or a cysteamine-containing composition improves immunity of animals, two experiments of which are described in detail as follows.

EXPERIMENTS

Experiment 1

Background Information

- 5 One hundred Holstein cows were used in the experiment. The average weight of the cows was about 600kg. The cows were pre-treated with two days of the cysteamine-containing composition as described above. The actual experiment lasted for thirteen weeks.

10

Materials

- The cysteamine-containing composition being in mini-pill form comprised about 30wt% cysteamine together with other ingredients including cyclodextrin which served as a
15 stabilizer. The content of cyclodextrin in the composition was 10wt%. The composition was prepared by Walcom Bio-Chemicals Industry Limited.

Procedure

- 20 The cows were divided into a test group and a control group. The test group was administered with a predetermined amount of the cysteamine-containing composition via their cornmeal diet and the control group

was administered with no cysteamine-containing composition.
The cows were fed three times daily at 0730, 1430 and 2130.

Blood samples were collected from the cows at the end of
5 the fifth-week treatment period by caudal vein puncture. 2
ml of each of the blood samples were centrifuged at 1500
rpm for 15 minutes. The supernatants were pooled and
stored at -20°C for IL-2 analysis. IL-2 concentration was
determined with IL-2 RIA Kit (produced by Institute of
10 Radioimmunological Technique in Military Hospital, China).
The blood samples of the cows were also taken to determine
the number of leukocytes. IL-6 concentration was similarly
determined.

15 Data from the test and control groups of cows were analyzed
and presented as MEAN \pm STANDARD ERROR. Results from the
two groups of cows were compared by T-test.

Results and discussion

20 The test group of cows administered with 30g/day of the
cysteamine-containing composition had about 29% higher
serum concentration of IL-2 than that of the control group
of cows. Table 1 below summarizes the levels of IL-2, IL-6
and leukocytes of the two groups of cows.

Table 1

	IL-2 (ng/ml)	Leukocytes $10^3/L$	IL-6 in plasma (pg/ml)
Test cows	5.5 ± 0.29 (n=50)	9.12 (n=20)	309.36 ± 20.98 (n=37)
Control cows	4.3 (n=50)	10.8 (n=15)	251.86 ± 20.98 (n=39)

The 29% increase in IL-2 concentration is remarkably
 5 significant statistically ($P < 0.01$). It is to be noted
 that the number of peripheral blood leukocytes was also
 determined but it was found that there was no significant
 difference thereof between the test and control groups of
 cows. This indicates that the high concentration of IL-2
 10 detected was stimulated by the cysteamine-containing
 composition and not by other factors.

The results also show that the test group of cows had a
 22.8% higher plasma concentration of IL-6.

15

The experimental results indicate that cysteamine modulates
 and strengthens the immune system of animals by increasing
 the levels of IL-2 and IL-6.

20

Experiment 2

Background Information

Sixty-four Holstein cows were used in the experiment. The cows were randomly divided into a test group and a control
5 group, having thirty-two cows in each group.

Materials

The same cysteamine-containing composition used in Experiment I was used in this experiment.

10

Procedure

Starting from about twenty weeks after calving, each cow in the test group was administered with an initial amount of 20g/day of the cysteamine-containing composition. The
15 dosage of the cysteamine-containing composition was then gradually increased stepwise until 60g/day and then decreased to 30g/day towards the end of the experiment. The treatment with the cysteamine-containing composition lasted for 140 days. The cows were administered with the
20 cysteamine-containing composition via its diet. The diet comprises cornmeal powder. The control group of cows was not administered with any cysteamine-containing composition. The cows were fed three times daily.

At the end of the 140-day experimental period, blood samples of the two groups of cows were obtained through their caudal veins. The blood samples were mixed with heparin for anticoagulation. The blood samples were
5 incubated in a culture medium (RMPI 1640) and the white blood cells were isolated therefrom.

The isolated white blood cells from the samples of from the test group of cows were divided into two batches, with one
10 batch added with phytohemagglutnin (PHA) and the other batch added without any PHA. The two batches of blood samples were then added with ^3H -TdR and incubated for seventy-two hours.

15 The samples were then measured for the level of ^3H -TdR incorporation by scintillation counter. The level of ^3H -TdR incorporation was expressed in cpm.

The stimulation Index (SI) was then calculated based on the
20 following formula

$$\text{SI} = \frac{\text{mean cpm in T-cell cultured added with PHA}}{\text{mean cpm in T-cell cultured without PHA}}$$

The blood samples from the control group of cows were similarly treated and the SI thereof was calculated.

Results and discussion

- 5 Table 2 below summarizes the average SI values of the two groups of cows.

Table 2

10

Index	Group	Test	Control
	Stimulation Index (SI)	29.73±3.53*	21.85±2.07

*p < 0.05

- As shown in the Table 2, the SI index of test group of cows was 29.73±3.53 which is 36% higher than test of the control group of cows. The higher SI index means that there is a higher number of lymphocytes in the blood of the test group of cows indicating a generally improved immunity.
- 15

- 20 From the above two experiments, it is shown that cysteamine, or the cysteamine-containing composition, has effect in improving immunity of animals. In particular, cysteamine, or the cysteamine-containing composition has

effects in increasing the level of interleukin-2 and also stimulating production of T-cells.

Further studies have shown that cysteamine is particularly
5 effective in vertebrate animals in improving their immunity.

It is envisaged that with an improved immunity, farm with farm animals will be more productive. For example, farms
10 for raising meat-producing cattle will have a higher yield due to a lower death rate of the animals because of the improved immunity thereof. It is also envisaged that cysteamine or a cysteamine-containing composition according to the present invention may also be used in humans for
15 improving immunity of patients. For example, cysteamine may be used in combination with a conventional AIDS pharmaceutical for treating HIV infected patients.

The contents of each of the references discussed above,
20 including the references cited therein and the references listed below, are herein incorporated herein in their entirety. It is to be noted that numerous variations, modifications, and further embodiments are possible and accordingly, all such variations, modifications and

embodiments are to be regarded as being within the scope of the present invention.

References:

- 5 1. Besedovsky HO, del Rey A. 1992. Immune-neuroendocrine circuits: integrative role of cytokines. Front Neuroendocrinol 13(1):61-94
2. Auernhammer CJ, Strasburger CJ. 1995. Effects of growth hormone and insulin-like growth factor I on the immune
10 system. Eur J Endocrinol 133(6):635-45
3. Khosraviani M, Davis SL. 1996. Hormonal regulation of peripheral blood mononuclear cells in sheep. Domest Anim Endocrinol 13(2):139-50
- 15 4. Torre PM, Lewis MJ, Ingle TL, Oliver SP. 1993. Influence of recombinant bovine somatotropin (sometribove) on mononuclear cells during the nonlactating period. J Dairy Sci 1993 Apr; 76(4):983-91
- 20 5. Szabo S, Reichlin S. 1981. Somatostatin in rat tissues is depleted by cysteamine administration. Endocrinology 109(6): 2255-7

6. Millard WJ, Sagar SM, Badger TM, Martin JB.1983.
Cysteamine effects on growth hormone secretion in the
male rat. Endocrinology 112(2):509-17
- 5 7. McGuffet RK, Green HB, Basson RP, Ferguson TH. 1990.
Lactation response of dairy cows receiving bovine
somatotropin via daily injection or in a sustained-
release vehicle. J Dairy Sci. 73:763-771

CLAIMS:-

1. The use of cysteamine, a salt thereof, or a composition containing cysteamine or a salt thereof, for improving
5 immunity of animals.
2. The use according to Claim 1, wherein said improving immunity includes increasing the level of interleukin-2 (IL-2) in said animals.
3. The use according to Claim 1 or 2, wherein said
10 improving immunity includes increasing the level of interleukin-6 (IL-6) in said animals.
4. The use according to Claim 1, 2 or 3, wherein said improving immunity includes stimulating production of lymphocytes in said animals.
- 15 5. The use according to any preceding claim, wherein said animals are vertebrate animals.
6. The use according to any preceding claim, wherein said composition comprises 1 to 95wt% of cysteamine, or a salt thereof, and an inclusion compound host materials
20 composition comprising a stabilizer selected from a group including cyclodextrin and its derivatives.
7. The use according to Claim 6, wherein said cysteamine-containing composition comprises 1 to 60wt% of said inclusion compound host materials composition.

8. The use according to any preceding claim, wherein said cysteamine-containing composition comprises at least one of fillers, disintegrants, binders, and flavorings and smelling agents.

5 9. The use according to any preceding claim, wherein said cysteamine-containing composition comprises coating materials.

10. The use according to Claim 9, wherein said cysteamine-containing composition comprises 1 to 20wt% of said
10 coating materials.

11. The use according to Claim 9 or 10, wherein said coating materials are enteric.

12. The use according to any one of Claims 9 to 11, wherein said coating materials are selected from a group
15 including cellulose acetate phthalate, starch acetate phthalate, methyl cellulose phthalate, glucose or fructose derivatives from phthalic acid, acrylic and methacrylic copolymers, polymethyl vinyl ether, partly esterified substance of maleic anhydride copolymer and
20 formogelatine.

13. The use according to Claim 8, wherein said cysteamine-containing composition comprises 1 to 90wt% of said fillers.

14. The use according to Claim 8 or 13, wherein said fillers are selected from a group including powdered cellulose, starch and calcium sulfate.

15. The use according to Claim 8, 13 or 14, wherein said
5 cysteamine-containing composition comprising 5 to 50wt% of said binders and said disintegrants.

16. The use according to any one of Claims 8 and 13 to 15, wherein said binders and said disintegrants are selected from a group including hydropropyl starch, microbial
10 alginate, microcrystalline cellulose and starch.

17. The use according to any one of Claims 8 and 13 to 16, wherein said cysteamine-containing composition comprises 0.05 to 0.3wt% of said flavoring and smelling agents for enhancing the flavor thereof.

15 18. The use according to any one of Claims 9 to 12, wherein said cysteamine-containing composition is formed into granules, each of which comprises at least one layer of said coating materials.

19. The use according to Claim 6 or 7, wherein said
20 cysteamine-containing composition is formed into granules in which the cysteamine or a salt thereof is shielded from its surroundings by said inclusion compound host materials composition.

20. The use according to Claim 18 or 19, wherein each of said granules of said cysteamine-containing composition has a size ranging from 0.28 to 0.90mm in diameter.

21. The use according to Claim 11, wherein said cysteamine-containing composition is encapsulated by said enteric coating materials.

22. The use according to any preceding claim for the manufacture of an animal feed additive.

23. The use according to any preceding claim for the manufacture of an animal feed.

24. A composition for improving immunity of animals, comprising cysteamine or a salt thereof.

25. A composition according to Claim 24, wherein said improving immunity includes increasing the level of interleukin-2 (IL-2) in said animals.

26. A composition according to Claim 24 or 25, wherein said improving immunity includes increasing the level of interleukin-6 (IL-6) in said animals.

27. A composition according to Claim 24, 25 or 26, wherein said improving immunity includes stimulating production of lymphocytes in said animals.

28. A composition according to any one of Claims 24 to 27, wherein said animals are vertebrate animals.

29. A composition according to any one of Claims 24 to 28,
comprising 1 to 95wt% of cysteamine, or a salt thereof,
and an inclusion compound host materials composition
comprising a stabilizer selected from a group including
5 cyclodextrin and its derivatives.

30. A composition according to Claim 29, wherein said
cysteamine-containing composition comprises 1 to 60wt%
of said inclusion compound host materials composition.

31. A composition according to any one of Claims 24 to 30,
10 wherein said cysteamine-containing composition comprises
at least one of fillers, disintegrants, binders, and
flavorings and smelling agents.

32. A composition according to any one of Claims 24 to 31,
wherein said cysteamine-containing composition comprises
15 coating materials.

33. A composition according to Claim 32, wherein said
cysteamine-containing composition comprises 1 to 20wt%
of said coating materials.

34. A composition according to Claim 32 or 33, wherein said
20 coating materials are enteric.

35. A composition according to any one of Claims 32 to 34,
wherein said coating materials are selected from a group
including cellulose acetate phthalate, starch acetate
phthalate, methyl cellulose phthalate, glucose or

fructose derivatives from phthalic acid, acrylic and methacrylic copolymers, polymethyl vinyl ether, partly esterified substance of maleic anhydride copolymer and formogelatine.

5 36.A composition according to Claim 31, wherein said cysteamine-containing composition comprises 1 to 90wt% of said fillers.

37.A composition according to Claim 31 or 36, wherein said fillers are selected from a group including powdered
10 cellulose, starch and calcium sulfate.

38.A composition according to Claim 31, wherein said cysteamine-containing composition comprising 5 to 50wt% of said binders and said disintegrants.

39.A composition according to Claim 31 or 38, wherein said
15 binders and said disintegrants are selected from a group including hydropropyl starch, microbial alginate, microcrystalline cellulose and starch.

40.A composition according to Claim 31, wherein said cysteamine-containing composition comprises 0.05 to
20 0.3wt% of said flavoring and smelling agents for enhancing the flavor thereof.

41.A composition according to any one of Claims 32 to 40, wherein said cysteamine-containing composition is formed

into granules, each of which comprises at least one layer of said coating materials.

42. A composition according to Claim 29 or 30, wherein said cysteamine-containing composition is formed into granules in which the cysteamine or a salt thereof is shielded from its surroundings by said inclusion compound host materials composition.

43. A composition according to Claim 41 or 42, wherein each of said granules of said cysteamine-containing composition has a size ranging from 0.28 to 0.90mm in diameter.

44. A composition according to Claim 34, wherein said cysteamine-containing composition is encapsulated by said enteric coating materials.

45. An animal feed additive for improving immunity of animals comprising cysteamine, a salt thereof, or a cysteamine-containing composition as defined in any one of Claims 24 to 44.

46. An animal feed for improving immunity of animals comprising a cysteamine, a salt thereof, or a cysteamine-containing composition as defined in any one of Claims 24 to 44.

47. A method for improving immunity of animals comprising administering cysteamine, a salt thereof or a

composition as defined in any one of Claims to 24 to 44
in animals.

48. The use of cysteamine, a salt thereof, or a composition
containing cysteamine or a salt thereof, substantially
5 as hereinbefore described.

49. A composition for improving immunity of animals
substantially as hereinbefore described.

50. An animal feed additive for improving immunity of
animals substantially as hereinbefore described.

10 51. An animal feed for improving immunity of animals
substantially as hereinbefore described.

52. A method for improving immunity of animals substantially
as hereinbefore described.



INVESTOR IN PEOPLE

Application No: GB 0303843.7
Claims searched: 1-52

Examiner: Dr William Thomson
Date of search: 17 July 2003

Patents Act 1977 : Search Report under Section 17

Documents considered to be relevant:

Category	Relevant to claims	Identity of document and passage or figure of particular relevance
X	1 and 24 at least	US 5605885 (BERNTON ET AL) See whole document, in particular column 5, lines 5-8, column 8, lines 29-33, column 8, line 57 - column 9, line 2, Example 1
X	1 and 24 at least	"Cysteamine Produces Dose-Related Bidirectional Immunomodulatory Effect in Mice" H. Bryant et al, J of Pharmacology and Experimental Therapeutics, 1989, 249(2), 424-429 See abstract and discussion
X	1 and 24 at least	WO 99/39707A1 (WINTHROP-UNIVERSITY HOSPITAL) See whole document, in particular page 2, line 27 - page 5, line 15, page 13, lines 24-31 and claims 1, 12 and 18
X	24 and 29 at least	FR 2716625A1 (GOUCHET) See whole document, in particular the Examples and claims 1-10
X	24 at least	WO 00/66110A1 (MERCK PATENT GMBH) See whole document, in particular page 3, lines 5-23, page 6, lines 4-13 and claims 1-4
X	24 at least	US 4657932 (MARTIN ET AL) See whole document, in particular column 5, lines 8-24, the Example and claims 1-5
X	45 and 46 at least	WO 03/009699A2 (WALCOM) See whole document, in particular the Examples and claims 1-39
X	45 and 46 at least	WO 02/48110A2 (WALCOM) See whole document, in particular, the Examples and claims 1-41



INVESTOR IN PEOPLE

Application No: GB 0303843.7
Claims searched: 1-52

Examiner: Dr William Thomson
Date of search: 17 July 2003

Categories:

X Document indicating lack of novelty or inventive step	A Document indicating technological background and/or state of the art.
Y Document indicating lack of inventive step if combined with one or more other documents of same category.	P Document published on or after the declared priority date but before the filing date of this invention.
& Member of the same patent family	E Patent document published on or after, but with priority date earlier than, the filing date of this application.

Field of Search:

Search of GB, EP, WO & US patent documents classified in the following areas of the UKC^v:

--

Worldwide search of patent documents classified in the following areas of the IPC⁷:

A61K, A61P

The following online and other databases have been used in the preparation of this search report:

CAS-ONLINE, EPODOC, JAPIO, TXTE & WPI

THIS PAGE BLANK (USPTO)